BioSpace News Archive

Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Moderna, Inc. (Nasdaq:MRNA) and Generation Bio Co. (Nasdaq:GBIO) today announced that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core technologies of Generation Bio’s non-viral genetic medicine platform.

Mercy BioAnalytics, Inc. today announced that it has added two senior executives as the Company transitions from research to clinical development. Toumy Guettouche, PhD has joined Mercy as the Chief Scientific Officer, and Michael Smith has joined as the company’s first Vice President for Quality, Regulatory, and Clinical Affairs.

CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association.

Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”) (LSE:HEMO) is pleased to announce the successful completion of a full set of analytical tests required to verify the quality of the cells manufactured during three Process Qualification (“PQ”) runs of the end-to-end process for HEMO-CAR-T production.

Curia, a leading contract research, development and manufacturing organization, announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally.

NeuroRPM Inc., a digital health company, has received FDA clearance for NeuroRPM, a breakthrough product that uses AI and Apple Watch to continuously and passively monitor bradykinesia, tremor, and dyskinesia, the cardinal symptoms of Parkinson’s disease.

Arcade Therapeutics (fka Wise Therapeutics) announced topline results of their StarStarter Rx Pilot Study, evaluating the efficacy and safety of their flagship digital therapeutic in adults 22-65 with Social Anxiety Disorder (SAD).

Aquavit Pharmaceuticals, Inc. announced that the company’s technology patent for “Methods for Delivering Bioactive Compositions and Formulations Using Microchannel Delivery Device” has been approved for publishing by the World Intellectual Property Organization.

Galapagos NV publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting,to be held on Tuesday 25 April 2023, at 2:00 p.m., at the registered office of the company.